Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Horse antibodies show promise against severe COVID-19 in clinical trial

NCT ID NCT04494984

Disease control Sponsor: Inmunova S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a treatment called INM005, made from antibodies produced in horses, for adults hospitalized with moderate to severe COVID-19. The goal was to see if it could help patients recover faster, measured by improvement on a standard health scale 28 days after treatment. A total of 243 participants received either the serum or a placebo, and researchers tracked their recovery and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

243 people

The number who actually took part.

Started

Jul 2020

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects of both sexes aged 18 to 79 years of age 2. SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) for virus detection 3. Patients with moderate or severe disease by NIH definition, which requires hospitalization. 4. Acceptance to participate in the study by the signature of the informed consent by a subject or their relative, if applicable 5. Be within 10 days of the onset of symptoms at the time of the Screening visit according to a case definition from the National Ministry of Health 6. Female patients of child-bearing age with negative pregnancy test Exclusion Criteria: 1. Patients who have received treatment with plasma from COVID-19 convalescents. 2. Patients who are participating in other therapeutic clinical trials 3. Patients who require mechanical respiratory assistance or are hospitalized in the ICU at the time of the screening visit. 4. History of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. 5. Pregnant or breastfeeding women 6. Patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease 7. Patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

Contacts and locations

Locations

  • Centro Gallego de Buenos Aires

    Ciudad Autonoma de Buenos Aire, Argentina

  • Clínica Adventista Belgrano

    Ciudad Autonoma de Buenos Aire, Argentina

  • Clínica Zabala

    Ciudad Autonoma de Buenos Aire, Argentina

  • Hospital Alta Complejidad "El Cruce" Dr. Néstor Carlos Kirchner

    San Juan Bautista, Buenos Aires, Argentina

  • Hospital Centro de Salud Zenón J. Santillán

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Hospital Español de Buenos Aires

    Ciudad Autonoma de Buenos Aire, Argentina

  • Hospital Italiano de Buenos Aires

    Buenos Aires, C1199ABH, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina

  • Hospital Municipal Dr. Diego E. Thompson

    San Martín, Buenos Aires, Argentina

  • Hospital Municipal Emilio Zerboni

    San Antonio de Areco, Buenos Aires, Argentina

  • Hospital Muñiz

    Buenos Aires, C1282AEN, Argentina

  • Hospital Pirovano

    Buenos Aires, C1428, Argentina

  • Hospital Prof. Dr. Bernardo A. Houssay

    Florida, Buenos Aires, Argentina

  • Hospital Provincial Neuquén "Dr. Eduardo Castro Rendón"

    Neuquén, Neuquén Province, Argentina

  • Hospital de Cuenca Alta

    Canuelas, Buenos Aires, B1814, Argentina

  • Instituto Medico Platense

    La Plata, Buenos Aires, B1900AVG, Argentina

  • Sanatorio Agote

    Ciudad Autonoma de Buenos Aire, Argentina

  • Sanatorio Guemes

    Buenos Aires, C1180AAD, Argentina

  • Sanatorio Sagrado Corazón

    Ciudad Autonoma de Buenos Aire, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.